Table 2. Comparison of the expression of CYP4’s in normal colonic mucosa, primary colorectal cancer and lymph node metastasis.

	Immunoreactivity (P-value, normal vs primary tumour)	Change in expression in tumour	Immunoreactivity (P-value, primary tumour vs lymph node metastasis)	Change in expression in lymph node	Immunoreactivity (P-value, paired primary Dukes C tumour vs lymph node metastasis)	Change in expression in lymph node
CYP4A11	P<0.001	↑	P=0.007	↓	P=0.002	↓
CYP4F11	P<0.001	↑	P<0.001	↓	P<0.001	↓
CYP4V2	P<0.001	↑	P<0.001	↓	P<0.001	↓
CYP4Z1	P=0.303	-	P=0.028	↓	P=0.083	-

Evaluation of normal colonic epithelium vs primary tumour samples for immunoreactivity (Mann–Whitney U-test, ↑=increased in tumour, ↓=decreased in tumour, - =no change between tumour and normal), and evaluation of primary Dukes C colorectal tumour samples and their corresponding metastasis samples for immunoreactivity (Wilcoxon signed-rank sum test, ↑=increased in lymph node metastasis, ↓=decreased in lymph node metastasis, - =no change between primary and metastatic tumour). Significant values are highlighted in bold.